Profile
Mark Conley served as the Director-Global Finance at Thermo Fisher Scientific, Inc. from 2007 to 2012.
He then worked as the Operations Controller at Haemonetics Corp.
from 1991 to 1996.
From 2005 to 2007, he held the position of Vice President-Financial Planning & Analysis at Iron Mountain, Inc. Mr. Conley served as the Treasurer, Vice President & Controller at Valeritas Holdings, Inc. from 2016 to 2020.
He also worked as the Chief Financial Officer & Controller at HoltraChem, Inc. from 1996 to 1998.
In 2020, he became the Vice President-Finance at Kaleido Biosciences, Inc. Currently, Mr. Conley is serving as the Chief Financial Officer, Treasurer, CAO & VP at Radius Health, Inc. His educational background includes an undergraduate degree from Oklahoma State University in 1983 and an MBA from Bryant University in 1999.
Former positions of Mark Conley
| Companies | Position | End |
|---|---|---|
| RADIUS HEALTH, INC. | Director of Finance/CFO | 2024-04-28 |
| KALEIDO BIOSCIENCES, INC. | Corporate Officer/Principal | 2022-02-28 |
| VALERITAS HOLDINGS, INC. | Comptroller/Controller/Auditor | 2020-01-12 |
| THERMO FISHER SCIENTIFIC | Director of Finance/CFO | 2011-12-31 |
| IRON MOUNTAIN INCORPORATED | Comptroller/Controller/Auditor | 2003-12-31 |
Training of Mark Conley
| Oklahoma State University | Undergraduate Degree |
| Bryant University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| HAEMONETICS CORPORATION | Health Technology |
| IRON MOUNTAIN INCORPORATED | Finance |
| THERMO FISHER SCIENTIFIC | Health Technology |
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Valeritas Holdings, Inc.
 Valeritas Holdings, Inc. Medical SpecialtiesHealth Technology Valeritas Holdings, Inc. develops and commercializes insulin delivery devices. The company was founded by Leisa Swanson and Robert R. Gonnelli on August 2, 2006 and is headquartered in Bridgewater, NJ. | Health Technology |
HoltraChem, Inc.
 HoltraChem, Inc. Wholesale DistributorsDistribution Services Part of Pressure Vessel Service, Inc., HoltraChem, Inc. distributes alkalies and chlorine chemicals. The private company is based in Natick, MA. HoltraChem was acquired by Pressure Vessel Service, Inc. on October 29, 1998. | Distribution Services |
- Stock Market
- Insiders
- Mark Conley